fbpx

Terapi Antikò Monoklonal

Terapi Antikò Monoklonal pou KOVID-19

Tretman antikò monoklonal yo ka anpeche maladi grav, etène lopital epi mouri lakay pasyan ki ap kouri gro risk ki te pran oubyen ki te ekspoze ak KOVID-19. Tretman sa yo disponib anpil kote nan Florid.

  • Ou pap peye okenn lajan pou tretman an e ke w pran vaksen an oubyen w pa t pran l sa pa gen enpòtans. Si w gen 12 an e plis ke sa e w gen gro risk pou gen maladi grav akòz KOVID-19, ou kalifye pou tretman sa.
  • Nan tès klinik yo, tretman antikò monoklonal te montre gen yon diminisyon de 70% nan moun k ap etène lopital ak moun ki mouri yo.
  • Pou pasyan k ap kouri gro risk yo ki te ekspoze ak yon moun ki gen KOVID-19, Regeneron ka ba w yon iminite pou yon titan pou diminye chans ou pou trape enfeksyon an a plis ke 80%.

 

 

Tretman antikò monoklonal yo ka preskri pa founisè swen sante yo bay moun ki gen 12 an oubyen plis ke yo te dekouvri ki gen KOVID-19 e ki te ekspoze ak moun ki gen KOVID-19 e ki gen gro risk pou gen maladi grav epi etène lopital.

Sepandan, pou sipòte inisyativ Gouvènè DeSantis a, genyen pou kounye a yon lòd pèmanan standing order nan Florid ki te siyen pa Chirijyen Jeneral Eta a ki pèmèt pasyan yo resevwa tretman sa san preskripsyon oswa referans depi se yon founisè swen sante kalifye ki bay li. Kalite referans sa yo pa nesesè nan nenpòt lokal tretman antikò monoklonal Eta Florid la epi tretman yo disponib gratis pou pasyan yo.

Antikò yo ede sistèm iminitè a rekonèt epi reponn efikasman ak viris la. Daprè enstriksyon tretman yo  the treatment guidelines , yo dwe bay yo tousuit aprè egzamen. Lè l bay aksè ak tretman sa yo nan nouvo lokal sa yo, Gouvènè DeSantis ap redui demann resous lopital yo e anplis asire l ke abitan Florid yo gen aksè ak tout tretman posib ki ka ede yo jwenn sante ankò aprè yo te gen KOVID-19.

Pou plis enfòmasyon, rele nimewo asistans Depatman Sante Tretman Antikò Monoklonal Florid la nan: 850-344-9637.

Monoclonal antibodies help the immune system recognize and respond more effectively to the COVID-19 virus.

Monoclonal antibodies are a treatment authorized by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) for use in adult and pediatric patients (12 and older) who have either been diagnosed or exposed to someone with COVID-19 and are at high risk for progression to severe illness, hospitalization, or death from COVID-19.

In clinical trials, this treatment resulted in a 70% reduction in risk for hospitalization and death, and resulted in an 82% reduction in risk for contracting COVID-19 for people who were exposed to the virus by other members of their household.

Monoclonal antibody treatment is most effective when given early and the sooner it is given the better. There is not a time limit to receive the medication, however it must be delivered prior to the occurrence of severe illness.

This treatment is available to all eligible people, regardless of vaccination status.

High-risk patients should get treatment as quickly as possible after testing positive for COVID- 19. Examples of medical conditions that may pose a higher risk for severe illness and could potentially benefit from this treatment include, but are not limited to:

  • Older age (65 years of age and older)
  • Individuals overweight
  • Chronic kidney disease
  • Diabetes
  • Pregnancy
  • Immunosuppressive disease or treatments
  • Cardiovascular disease
  • Chronic lung diseases
  • Sickle cell disease
  • Neurodevelopmental disorders such as cerebral palsy
  • Having medical-related technological dependence such as tracheostomy or gastrostomy

There is no cost for monoclonal antibody treatment. No one will be denied services due to inability to pay for administrative cost at State of Florida sites. However, insurance can be billed if available.

At the direction of Governor DeSantis, the Florida Department of Health and Florida Division of Emergency Management are working together to deploy mobile and stationary monoclonal antibody therapy treatment sites. Click here to find a monoclonal antibody treatment site.

To support Governor DeSantis’ initiative, there is currently a standing order in Florida signed by the State Surgeon General that allows patients to receive this treatment without a prescription or referral if administered by an eligible health care provider. Such referrals are not required at any of the State of Florida monoclonal antibody treatment sites.